A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed

[1] Hsu KH(2015)Identification of five driver gene mutations in patients with treatment-naive lung adenocarcinoma in Taiwan PLoS One 10 4107-4114

[2] Wang R(2014)FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer Clin Cancer Res 20 2251-2258

[3] Solomon BJ(2018)Final overall survival analysis from a study comparing first-line Crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung Cancer J Clin Oncol 36 21903-21917

[4] Duruisseaux M(2017)Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study Oncotarget 8 2167-2177

[5] Solomon BJ(2014)First-line crizotinib versus chemotherapy in ALK-positive lung cancer N Engl J Med 371 3-199

[6] Bang Y(2010)Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) J Clin Oncol 28 195-838

[7] Nakagawa K(2020)Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer Lung Cancer 139 829-690

[8] Peters S(2017)Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung Cancer N Engl J Med 377 679-5690

[9] Sakamoto H(2011)CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant Cancer Cell 19 5675-1494

[10] Marsilje TH(2013)Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials J Med Chem 56 1484-582

[1] Hsu KH(2015)Identification of five driver gene mutations in patients with treatment-naive lung adenocarcinoma in Taiwan PLoS One 10 4107-4114

[2] Wang R(2014)FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer Clin Cancer Res 20 2251-2258

[3] Solomon BJ(2018)Final overall survival analysis from a study comparing first-line Crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung Cancer J Clin Oncol 36 21903-21917

[4] Duruisseaux M(2017)Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study Oncotarget 8 2167-2177

[5] Solomon BJ(2014)First-line crizotinib versus chemotherapy in ALK-positive lung cancer N Engl J Med 371 3-199

[6] Bang Y(2010)Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) J Clin Oncol 28 195-838

[7] Nakagawa K(2020)Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer Lung Cancer 139 829-690

[8] Peters S(2017)Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung Cancer N Engl J Med 377 679-5690

[9] Sakamoto H(2011)CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant Cancer Cell 19 5675-1494

[10] Marsilje TH(2013)Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials J Med Chem 56 1484-582